免疫检查点抑制剂主要内分泌不良反应急症处理中国专家共识

Chinese expert consensus on immune checkpoint inhibitors induced emergency management of endocrine adverse reactions

摘要:

免疫检查点抑制剂（immune checkpoint inhibitors，ICPis）是新兴的抗肿瘤药物，内分泌不良反应是其较为常见的药物不良反应，主要累及多个内分泌腺如甲状腺、垂体、肾上腺和胰腺等，导致内分泌功能紊乱。其急症如不能在早期得到正确的鉴别和防治，可能会危及生命。国内外虽已推出相关指南/共识多部，但国内尚无针对ICPis导致内分泌不良反应急症的诊治流程和共识。为规范和提高相关科室临床诊治水平，本共识回顾分析了多项国内外专家共识和临床研究，综合肿瘤学、内分泌学和护理学专家意见后制订本共识。

Abstract:

Immune checkpoint inhibitors (ICPis) are emerging anti-tumor drugs, with endocrine adverse reactions as its most common adverse drug reactions, and mainly involves multiple endocrine glands, such as glands of thyroid, pituitary, adrenal and pancreas, leading to endocrine dysfunction. If its emergencies can not be correctly identified and prevented in the early stage, it may be life-threatening. Although a number of relevant guidelines/consensuses have been published at home and abroad, there is no consensus on the diagnosis and treatment process of endocrine adverse reactions caused by ICPis in China. In order to standardize and improve the clinical diagnosis and treatment level of relevant departments, we have reviewed and analyzed a number of domestic and international expert consensuses and clinical studies, and formulated this consensus based on integration of the opinions of oncology, endocrinology and nursing experts.